{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-23-000048","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.613476+00:00","generated_at":"2026-06-13T21:19:38.375034+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Recursion reports stockholder meeting results; all four proposals approved","bullets":["Terry-Ann Burrell and Christopher Gibson elected Class II directors with 163.4M and 169.4M votes for.","Advisory vote on executive compensation approved with 178.8M for (98.9% of votes cast).","Stockholders favored an annual advisory vote on executive compensation (180.1M for 1 year).","Ratification of Ernst & Young as independent auditor for FY 2023 approved with 210.6M for."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-23-000048","json":"https://secwatch.observer/filing/0001601830-23-000048.json","markdown":"https://secwatch.observer/filing/0001601830-23-000048.md","text":"https://secwatch.observer/filing/0001601830-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/rxrx-20230616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:19:38.375034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e3fcf7e0812e9f25d1ff87418f08540629fbc69","claim":"RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory resolution to approve executive compensation at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes 178,827,946 1,734,461 326,236 29,965,701","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"284d09bc55772d70eb02b7ecea458617f2451396","claim":"RECURSION PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 4: The appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2023 was ratified, with the following votes cast: For Against Abstain 210,585,521 71,005 197,818","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"3d16dd9ca080dd0020779597d39fb2ab089ef905","claim":"RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Terry-Ann Burrell as Class II director at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Terry-Ann Burrell, M.B.A. 163,422,186 17,466,457 29,965,701 Christopher Gibson, Ph.D. 169,410,560 11,478,083 29,965,701","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"6a25023e750ff6146c910f8c64acd9bf180cb077","claim":"RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Christopher Gibson as Class II director at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Terry-Ann Burrell, M.B.A. 163,422,186 17,466,457 29,965,701 Christopher Gibson, Ph.D. 169,410,560 11,478,083 29,965,701","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"b0360126cf617917c5c168a4b8cf950a47ef2e85","claim":"RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory vote on the frequency of the advisory vote on executive compensation at the 2023-06-16 meeting.","evidence_excerpt":"Proposal 3: The advisory vote on the frequency of the advisory vote on executive compensation favored an annual vote, with the following votes cast: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 180,126,697 17,141 598,617 146,188 29,965,701","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000048/0001601830-23-000048-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}